Browse Studies — Arctuva

Phase 1

AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-07994525 IN PARTICIPANTS WITH ADVANCED MALIGNANCIES

This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor …

Advanced MalignanciesAdvanced Cancer

Estimated

~$10 – $7,500

PfizerNCT07426757

Phase 1

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies

The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced …

Advanced MalignanciesOvarian CancerT-cell Lymphoma+1 more

Estimated

~$10 – $7,500

BioInvent International ABNCT04752826

Phase 1

A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants Who Were Previously Treated for Advanced Malignancies

The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor a…

Advanced Malignancies

Estimated

~$10 – $8,750

PharmaMarNCT07644039

Phase 3

An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indicati…

Hematologic MalignancySolid TumorAdvanced Malignancies

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06401356